Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 4/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 5/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | GBA2 | Q9HCG7 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18431148 | 0.88 | LMNA (0.40) | LMNAPOLBSMN1; SMN2RAB9ANPC1 | |
| SCHEMBL9806686 | 0.87 | FFAR1 (0.43) | POLBRAB9ANPC1HPGDFFAR1 | |
| SCHEMBL18431147 | 0.86 | RAB9A (0.48) | LMNAPOLBSMN1; SMN2RAB9ANPC1 | |
| SCHEMBL2913340 | 0.86 | POLB (0.47) | LMNAPOLBSMN1; SMN2RAB9ANPC1 | |
| SCHEMBL3036913 | 0.84 | LMNA (0.42) | LMNAPOLBSMN1; SMN2RAB9ANPC1 | |
| SCHEMBL6119301 | 0.83 | MAPT (0.43) | LMNAPOLBSMN1; SMN2RAB9ANPC1 | |
| SCHEMBL14144107 | 0.82 | POLB (0.45) | LMNAPOLBSMN1; SMN2RAB9ANPC1 | |
| SCHEMBL31648060 | 0.82 | MAPT (0.43) | LMNAPOLBSMN1; SMN2RAB9ANPC1 | |
| SCHEMBL6336988 | 0.82 | MAPT (0.43) | LMNAPOLBSMN1; SMN2RAB9ANPC1 | |
| SCHEMBL9761016 | 0.82 | MAPT (0.43) | LMNAPOLBSMN1; SMN2RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170247355-A1 | PROTEOSTASIS REGULATORS | PROTEOSTASIS THERAPEUTICS, INC. | 2017-08-31 | — | — | US | disclosed |
| US-9556166-B2 | Proteostasis regulators | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2017-01-31 | — | — | US | disclosed |
| EP-1406897-A2 | COMPOUNDS | SmithKline Beecham plc (GB) | 2004-04-14 | — | — | EP | disclosed |
| WO-2003002559-A2 | PIPERIDINE COMPOUNDS FOR USE AS OREXIN RECEPTOR ANTAGONIST | SMITHKLINE BEECHAM P.L.C. (GB) | 2003-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170247355-A1 | PROTEOSTASIS REGULATORS | PSMG3, VCP, HSPA5 | LMNA 769/4885POLB 2527/4885SMN1; SMN2 595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.